selected publications
- IL10R Inhibition Induces Neutrophil Tumoricidal Activity. Cancer immunology research. 2026 Academic Article GET IT
- Antimicrobial Exposure and Immune-Related Cutaneous Adverse Events During Immune Checkpoint Blockade Therapy. JAMA dermatology. 2026 Academic Article GET IT
- Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026 Article GET IT
-
An ultrasmall core-shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments.
Nature nanotechnology.
2025
Academic Article
GET IT
Times cited: 4 -
Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.
Nature immunology.
2025
Academic Article
GET IT
Times cited: 3 - Changing Role of Adjuvant Therapy in Stage III Melanoma. The New England journal of medicine. 2025 Editorial Article GET IT
-
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2025
Academic Article
GET IT
Times cited: 9 -
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profiling.
Nature methods.
2025
Academic Article
GET IT
Times cited: 10 -
Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer.
Cancer immunology research.
2025
Academic Article
GET IT
Times cited: 1 -
Nivolumab plus Ipilimumab in Advanced Melanoma. Reply.
The New England journal of medicine.
2025
Article
GET IT
Times cited: 2 -
RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer.
Nature.
2025
Academic Article
GET IT
Times cited: 182 -
Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma.
Journal for immunotherapy of cancer.
2024
Article
GET IT
Times cited: 1 -
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
European journal of cancer (Oxford, England : 1990).
2024
Academic Article
GET IT
Times cited: 12 -
Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma.
Cell reports. Medicine.
2024
Academic Article
GET IT
Times cited: 5 -
Intermittent MEK Inhibition with GITR Costimulation Rescues T-cell Function for Increased Efficacy with CTLA-4 Blockade in Solid Tumor Models.
Cancer immunology research.
2024
Academic Article
GET IT
Times cited: 6 -
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
The New England journal of medicine.
2024
Academic Article
GET IT
Times cited: 354 -
Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models.
The Journal of clinical investigation.
2024
Academic Article
GET IT
Times cited: 58 -
TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models.
Molecular therapy. Oncology.
2024
Academic Article
GET IT
Times cited: 11 -
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2024
Academic Article
GET IT
Times cited: 6 - Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab. Pigment cell & melanoma research. 2024 Article GET IT
-
Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model.
Frontiers in oncology.
2024
Academic Article
GET IT
Times cited: 1 -
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
Nature medicine.
2024
Academic Article
GET IT
Times cited: 84 - Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects. Cancer cell. 2024 Academic Article GET IT
-
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.
Nature cancer.
2024
Academic Article
GET IT
Times cited: 14 -
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
European journal of cancer (Oxford, England : 1990).
2023
Academic Article
GET IT
Times cited: 14 -
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
Cancer research communications.
2023
Academic Article
GET IT
Times cited: 7 -
APR-246 increases tumor antigenicity independent of p53.
Life science alliance.
2023
Academic Article
GET IT
Times cited: 5 -
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
Cancer cell.
2023
Academic Article
GET IT
Times cited: 37 -
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
Cancer cell.
2023
Academic Article
GET IT
Times cited: 146 -
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2023
Academic Article
GET IT
Times cited: 71 -
RECISTv1.1 progression in oncology: Shades of gray.
Cancer cell.
2023
Academic Article
GET IT
Times cited: 10 -
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
Nature.
2023
Academic Article
GET IT
Times cited: 1074 -
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs.
The Journal of experimental medicine.
2023
Academic Article
GET IT
Times cited: 18 -
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Pigment cell & melanoma research.
2023
Academic Article
GET IT
Times cited: 1 -
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Cancer cell.
2023
Academic Article
GET IT
Times cited: 64 -
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
The oncologist.
2023
Academic Article
GET IT
Times cited: 12 -
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Nature genetics.
2023
Academic Article
GET IT
Times cited: 131 -
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Cancer cell.
2023
Academic Article
GET IT
Times cited: 112 -
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Cell.
2023
Academic Article
GET IT
Times cited: 239 -
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.
The Lancet. Oncology.
2023
Information Resource
GET IT
Times cited: 24 -
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2023
Editorial Article
GET IT
Times cited: 54 -
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Immunity.
2022
Academic Article
GET IT
Times cited: 91 -
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant.
NPJ vaccines.
2022
Academic Article
GET IT
Times cited: 9 -
Clinical implications of T cell exhaustion for cancer immunotherapy.
Nature reviews. Clinical oncology.
2022
Information Resource
GET IT
Times cited: 800 -
Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
Journal of the National Comprehensive Cancer Network : JNCCN.
2022
Academic Article
GET IT
Times cited: 19 -
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022
Academic Article
GET IT
Times cited: 372 -
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.
The Journal of clinical investigation.
2022
Academic Article
GET IT
Times cited: 20 -
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022
Academic Article
GET IT
Times cited: 41 -
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Science translational medicine.
2022
Academic Article
GET IT
Times cited: 24 -
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature.
2022
Article
GET IT
Times cited: 1 -
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.
Cancers.
2022
Academic Article
GET IT
Times cited: 17 -
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions.
The Journal of experimental medicine.
2022
Academic Article
GET IT
Times cited: 36 -
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer.
Nature.
2022
Academic Article
GET IT
Times cited: 166 -
Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Nature.
2022
Academic Article
GET IT
Times cited: 58 -
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Cancers.
2022
Academic Article
GET IT
Times cited: 16 -
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Nature communications.
2022
Academic Article
GET IT
Times cited: 73 -
Anatomic position determines oncogenic specificity in melanoma.
Nature.
2022
Academic Article
GET IT
Times cited: 66 - Reply to T. Olivier et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Article GET IT
-
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.
Science advances.
2022
Academic Article
GET IT
Times cited: 9 -
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Journal for immunotherapy of cancer.
2022
Academic Article
GET IT
Times cited: 43 -
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Academic Article
GET IT
Times cited: 46 -
In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology.
Scientific reports.
2021
Academic Article
GET IT
Times cited: 16 -
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2021
Academic Article
GET IT
Times cited: 974 -
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer.
Communications biology.
2021
Academic Article
GET IT
Times cited: 14 -
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Journal for immunotherapy of cancer.
2021
Academic Article
GET IT
Times cited: 112 -
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Journal for immunotherapy of cancer.
2021
Academic Article
GET IT
Times cited: 32 -
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness.
JCI insight.
2021
Academic Article
GET IT
Times cited: 5 -
Checkpoint blockade: the end of the beginning.
Nature reviews. Immunology.
2021
Information Resource
GET IT
Times cited: 16 -
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Journal for immunotherapy of cancer.
2021
Information Resource
GET IT
Times cited: 13 -
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways.
Nature reviews. Clinical oncology.
2021
Information Resource
GET IT
Times cited: 703 -
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
European journal of cancer (Oxford, England : 1990).
2021
Academic Article
GET IT
Times cited: 24 -
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Journal for immunotherapy of cancer.
2021
Academic Article
GET IT
Times cited: 18 -
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Science translational medicine.
2021
Academic Article
GET IT
Times cited: 86 -
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2021
Academic Article
GET IT
Times cited: 135 -
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Cancer immunology research.
2021
Academic Article
GET IT
Times cited: 105 -
Evidence generation and reproducibility in cell and gene therapy research: A call to action.
Molecular therapy. Methods & clinical development.
2021
Editorial Article
GET IT
Times cited: 17 - Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. Nature reviews. Rheumatology. 2021 Article GET IT
-
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child.
Nature medicine.
2021
Article
GET IT
Times cited: 106 -
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
Cell.
2021
Academic Article
GET IT
Times cited: 230 -
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot.
Cancer cell.
2021
Academic Article
GET IT
Times cited: 30 -
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity.
Cancer cell.
2021
Academic Article
GET IT
Times cited: 157 -
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors.
Immunity.
2021
Academic Article
GET IT
Times cited: 626 -
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.
Nature medicine.
2021
Academic Article
GET IT
Times cited: 421 -
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Cancer discovery.
2021
Academic Article
GET IT
Times cited: 244 -
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Oncoimmunology.
2021
Academic Article
GET IT
Times cited: 21 -
TNF in the era of immune checkpoint inhibitors: friend or foe?.
Nature reviews. Rheumatology.
2021
Information Resource
GET IT
Times cited: 140 -
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours.
Nature.
2021
Academic Article
GET IT
Times cited: 331 -
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer.
Research square.
2021
Article
GET IT
Times cited: 34 -
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021
Academic Article
GET IT
Times cited: 45 -
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma.
Cell reports.
2021
Academic Article
GET IT
Times cited: 46 -
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
Journal of immunotherapy (Hagerstown, Md. : 1997).
2021
Academic Article
GET IT
Times cited: 17 -
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
European journal of cancer (Oxford, England : 1990).
2020
Academic Article
GET IT
Times cited: 88 -
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Cancer cell.
2020
Article
GET IT
Times cited: 34 -
PD-L1 Blockade Therapy: Location, Location, Location.
Cancer cell.
2020
Article
GET IT
Times cited: 15 -
Immigration in science.
The Journal of experimental medicine.
2020
Academic Article
GET IT
Times cited: 3 -
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Cancer cell.
2020
Academic Article
GET IT
Times cited: 278 -
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Nature communications.
2020
Academic Article
GET IT
Times cited: 389 -
Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors.
American journal of ophthalmology case reports.
2020
Article
GET IT
Times cited: 15 -
Determinants of COVID-19 disease severity in patients with cancer.
Nature medicine.
2020
Academic Article
GET IT
Times cited: 503 -
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Academic Article
GET IT
Times cited: 33 -
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring.
Nature medicine.
2020
Academic Article
GET IT
Times cited: 315 -
The many faces of the anti-COVID immune response.
The Journal of experimental medicine.
2020
Academic Article
GET IT
Times cited: 429 -
The future of cancer immunotherapy: microenvironment-targeting combinations.
Cell research.
2020
Academic Article
GET IT
Times cited: 628 -
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers.
Cancer discovery.
2020
Academic Article
GET IT
Times cited: 207 - Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv : the preprint server for health sciences. 2020 Article GET IT
-
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Academic Article
GET IT
Times cited: 37 -
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
Journal for immunotherapy of cancer.
2020
Academic Article
GET IT
Times cited: 48 -
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity.
Nature.
2020
Academic Article
GET IT
Times cited: 305 -
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Nature immunology.
2020
Academic Article
GET IT
Times cited: 582 -
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2020
Academic Article
GET IT
Times cited: 178 -
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
Melanoma research.
2020
Academic Article
GET IT
Times cited: 27 -
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2020
Academic Article
GET IT
Times cited: 96 -
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Annals of surgical oncology.
2019
Academic Article
GET IT
Times cited: 52 -
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Nature immunology.
2019
Article
GET IT
Times cited: 5 -
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019
Academic Article
GET IT
Times cited: 212 -
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
JAMA oncology.
2019
Academic Article
GET IT
Times cited: 520 -
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
The New England journal of medicine.
2019
Academic Article
GET IT
Times cited: 3110 -
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading.
Ophthalmology.
2019
Academic Article
GET IT
Times cited: 30 -
Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.
The Journal of experimental medicine.
2019
Academic Article
GET IT
Times cited: 110 -
Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?.
Cancer cell.
2019
Article
GET IT
Times cited: 35 -
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 76 -
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Cell.
2019
Academic Article
GET IT
Times cited: 405 -
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.
European journal of cancer (Oxford, England : 1990).
2019
Academic Article
GET IT
Times cited: 160 -
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Nature immunology.
2019
Academic Article
GET IT
Times cited: 280 -
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
The Journal of clinical investigation.
2019
Academic Article
GET IT
Times cited: 40 -
Rational design of anti-GITR-based combination immunotherapy.
Nature medicine.
2019
Academic Article
GET IT
Times cited: 196 -
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.
Cell reports.
2019
Academic Article
GET IT
Times cited: 63 -
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
JAMA oncology.
2019
Academic Article
GET IT
Times cited: 573 -
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
Annals of oncology : official journal of the European Society for Medical Oncology.
2019
Academic Article
GET IT
Times cited: 790 -
Immunotherapy of Melanoma: Facts and Hopes.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019
Information Resource
GET IT
Times cited: 247 -
Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.
Oncoimmunology.
2019
Academic Article
GET IT
Times cited: 17 -
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
The oncologist.
2019
Article
GET IT
Times cited: 37 -
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
European journal of cancer (Oxford, England : 1990).
2019
Article
GET IT
Times cited: 23 - Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2019 Article GET IT
-
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Nature genetics.
2019
Academic Article
GET IT
Times cited: 3166 -
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Cancer immunology, immunotherapy : CII.
2018
Conference Paper
GET IT
Times cited: 9 -
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Article
GET IT
Times cited: 12 -
Putting the Immunologic Brakes on Cancer.
Cell.
2018
Information Resource
GET IT
Times cited: 92 -
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.
European journal of nuclear medicine and molecular imaging.
2018
Academic Article
GET IT
Times cited: 88 -
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Journal for immunotherapy of cancer.
2018
Article
GET IT
Times cited: 33 -
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2018
Academic Article
GET IT
Times cited: 149 -
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
The Lancet. Oncology.
2018
Academic Article
GET IT
Times cited: 1231 -
An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models.
International journal of radiation oncology, biology, physics.
2018
Academic Article
GET IT
Times cited: 91 -
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Cancer cell.
2018
Article
GET IT
Times cited: 60 -
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Cancer cell.
2018
Article
GET IT
Times cited: 17 -
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
The Journal of clinical investigation.
2018
Article
GET IT
Times cited: 24 -
Strategies for Predicting Response to Checkpoint Inhibitors.
Current hematologic malignancy reports.
2018
Information Resource
GET IT
Times cited: 29 -
The hallmarks of successful anticancer immunotherapy.
Science translational medicine.
2018
Information Resource
GET IT
Times cited: 475 -
Refusing to TAP out: 16 new human TEIPPs identified.
The Journal of experimental medicine.
2018
Article
GET IT
Times cited: 1 -
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 491 -
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Science translational medicine.
2018
Academic Article
GET IT
Times cited: 489 -
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Oncotarget.
2018
Academic Article
GET IT
Times cited: 30 -
Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 328 -
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 132 -
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Cancer discovery.
2018
Academic Article
GET IT
Times cited: 1375 -
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 270 -
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
The New England journal of medicine.
2018
Academic Article
GET IT
Times cited: 1729 -
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Cell.
2018
Academic Article
GET IT
Times cited: 141 -
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 886 -
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Cancer cell.
2018
Information Resource
GET IT
Times cited: 435 -
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
PloS one.
2018
Academic Article
GET IT
Times cited: 20 -
Cancer immunotherapy using checkpoint blockade.
Science (New York, N.Y.).
2018
Information Resource
GET IT
Times cited: 5525 -
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
The Journal of clinical investigation.
2018
Academic Article
GET IT
Times cited: 110 -
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 456 -
Introducing a New Series: Immunotherapy Facts and Hopes.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Editorial Article
GET IT
Times cited: 4 -
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Information Resource
GET IT
Times cited: 3202 -
Altered self: the not-so-neo-antigens.
Nature reviews. Immunology.
2018
Article
GET IT
Times cited: 1 -
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 335 -
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Cancer immunology research.
2018
Academic Article
GET IT
Times cited: 120 - Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name. Cancer journal (Sudbury, Mass.). 2018 Information Resource GET IT
-
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 414 -
Nivolumab and Ipilimumab in Advanced Melanoma.
The New England journal of medicine.
2017
Article
GET IT
Times cited: 19 -
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
JAMA oncology.
2017
Academic Article
GET IT
Times cited: 161 -
Future cancer research priorities in the USA: a Lancet Oncology Commission.
The Lancet. Oncology.
2017
Information Resource
GET IT
Times cited: 181 -
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Journal for immunotherapy of cancer.
2017
Academic Article
GET IT
Times cited: 108 -
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
Oncoimmunology.
2017
Academic Article
GET IT
Times cited: 31 -
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2017
Academic Article
GET IT
Times cited: 259 -
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
The New England journal of medicine.
2017
Academic Article
GET IT
Times cited: 3120 -
Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.
Science signaling.
2017
Academic Article
GET IT
Times cited: 123 -
Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.
Veterinary medicine and science.
2017
Academic Article
GET IT
Times cited: 13 -
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells.
Science immunology.
2017
Academic Article
GET IT
Times cited: 102 -
Checkpoint inhibition and melanoma: Considerations in treating the older adult.
Journal of geriatric oncology.
2017
Information Resource
GET IT
Times cited: 28 -
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 578 -
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.
Molecular therapy oncolytics.
2017
Academic Article
GET IT
Times cited: 83 -
Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.
Nature medicine.
2016
Article
GET IT
Times cited: 17 -
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
The New England journal of medicine.
2016
Academic Article
GET IT
Times cited: 1240 - Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. Journal of translational medicine. 2016 Academic Article GET IT
-
In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide.
Science immunology.
2016
Academic Article
GET IT
Times cited: 152 -
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
Melanoma research.
2016
Academic Article
GET IT
Times cited: 35 -
Patient-Physician Communication in the 21st Century.
Trends in immunology.
2016
Academic Article
GET IT
Times cited: 2 -
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2016
Article
GET IT
Times cited: 148 -
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
European journal of cancer (Oxford, England : 1990).
2016
Information Resource
GET IT
Times cited: 389 -
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.
Science advances.
2015
Academic Article
GET IT
Times cited: 162 -
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2015
Information Resource
GET IT
Times cited: 1232 -
Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma.
Molecular & cellular oncology.
2015
Academic Article
GET IT
Times cited: 37 -
Immunotherapy: The path to win the war on cancer?.
Cell.
2015
Academic Article
GET IT
Times cited: 94 -
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Cell research.
2015
Article
GET IT
Times cited: 19 -
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.
Frontiers in oncology.
2015
Information Resource
GET IT
Times cited: 211 -
Expanded access programmes: patient interests versus clinical trial integrity.
The Lancet. Oncology.
2014
Academic Article
GET IT
Times cited: 9 -
Immune modulation for cancer therapy.
British journal of cancer.
2014
Information Resource
GET IT
Times cited: 134 -
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2014
Academic Article
GET IT
Times cited: 141 -
The delicate balance of melanoma immunotherapy.
Clinical & translational immunology.
2013
Information Resource
GET IT
Times cited: 26 -
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology.
2013
Academic Article
GET IT
Times cited: 156 -
Emerging therapies in melanoma.
Clinical advances in hematology & oncology : H&O.
2012
Academic Article
GET IT
Times cited: 2 -
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2012
Information Resource
GET IT
Times cited: 57 -
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.
Cancer journal (Sudbury, Mass.).
2012
Information Resource
GET IT
Times cited: 63 -
Defining the critical hurdles in cancer immunotherapy.
Journal of translational medicine.
2011
Editorial Article
GET IT
Times cited: 145 -
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Oncogene.
2011
Academic Article
GET IT
Times cited: 178 -
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 70 -
Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs.
Journal of veterinary internal medicine.
2010
Academic Article
GET IT
Times cited: 58 -
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology.
2010
Academic Article
GET IT
Times cited: 477 -
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients.
Annals of oncology : official journal of the European Society for Medical Oncology.
2010
Academic Article
GET IT
Times cited: 28 - Can we use monoclonal antibodies to help T cells fight tumors?. Cytotherapy. 2006 Article GET IT
-
Cytokines in cytotherapy.
Cytotherapy.
2006
Academic Article
GET IT
Times cited: 1 -
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring.
Cytotherapy.
2006
Academic Article
GET IT
Times cited: 12 -
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.
Vaccine.
2005
Academic Article
GET IT
Times cited: 252 -
The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword.
Cancer cell.
2005
Article
GET IT
Times cited: 27 -
Persistence makes perfect: the benefits of IL-2 in adoptive immunotherapy.
Cytotherapy.
2005
Article
GET IT
Times cited: 1 -
Reassessing the usual suspects causing a commotion in the blood (and vessels?).
Cancer biology & therapy.
2004
Article
GET IT
Times cited: 1 -
Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Melanoma research.
2002
Academic Article
GET IT
Times cited: 11 -
Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.
Cancer immunity.
2001
Academic Article
GET IT
Times cited: 11 -
Vaccines for melanoma: translating basic immunology into new therapies.
The Lancet. Oncology.
2001
Information Resource
GET IT
Times cited: 41 -
Systemic chemotherapy.
Clinics in plastic surgery.
2000
Information Resource
GET IT
Times cited: 14 -
Management of renal cell carcinoma.
Oncology (Williston Park, N.Y.).
2000
Academic Article
GET IT
Times cited: 17 -
Vaccines and other adjuvant therapies for melanoma.
Hematology/oncology clinics of North America.
1998
Information Resource
GET IT
Times cited: 13 -
Treatment of Behçet disease with pentoxifylline.
Annals of internal medicine.
1997
Article
GET IT
Times cited: 4 -
Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation.
The Journal of investigative dermatology.
1995
Academic Article
GET IT
Times cited: 32 -
Activation of NF-kappa B may be necessary but is not sufficient for induction of H-2 antigens by TNF in J558L murine myeloma cells.
Journal of leukocyte biology.
1994
Academic Article
GET IT
Times cited: 6